These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

784 related items for PubMed ID: 20830787

  • 1. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline.
    Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL.
    Hepatology; 2010 Oct; 52(4):1251-7. PubMed ID: 20830787
    [Abstract] [Full Text] [Related]

  • 2. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ, Rijckborst V, Cakaloglu Y, Simon K, Heathcote EJ, Tabak F, Mach T, Boucher CA, Hansen BE, Zeuzem S, Janssen HL.
    Antivir Ther; 2012 Oct; 17(1):9-17. PubMed ID: 22267464
    [Abstract] [Full Text] [Related]

  • 3. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.
    Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Luo K, Wang Y, Hadziyannis S, Wolf E, McCloud P, Batrla R, Marcellin P.
    Hepatology; 2009 Apr; 49(4):1141-50. PubMed ID: 19338056
    [Abstract] [Full Text] [Related]

  • 4. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b.
    Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, So TM, Feinman SV, Mach T, Akarca US, Schutten M, Tielemans W, van Vuuren AJ, Hansen BE, Janssen HL.
    Gastroenterology; 2008 Aug; 135(2):459-67. PubMed ID: 18585385
    [Abstract] [Full Text] [Related]

  • 5. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.
    Rijckborst V, Hansen BE, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, Simon K, Akarca US, Flisiak R, Verhey E, Van Vuuren AJ, Boucher CA, ter Borg MJ, Janssen HL.
    Hepatology; 2010 Aug; 52(2):454-61. PubMed ID: 20683945
    [Abstract] [Full Text] [Related]

  • 6. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients.
    Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, Dauvergne A, Asselah T, Boyer N, Bedossa P, Valla D, Vidaud M, Nicolas-Chanoine MH, Marcellin P.
    Hepatology; 2009 Apr; 49(4):1151-7. PubMed ID: 19115222
    [Abstract] [Full Text] [Related]

  • 7. Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B.
    Sonneveld MJ, Rijckborst V, Zeuzem S, Heathcote EJ, Simon K, Senturk H, Pas SD, Hansen BE, Janssen HL.
    Hepatology; 2012 Jul; 56(1):67-75. PubMed ID: 22307831
    [Abstract] [Full Text] [Related]

  • 8. Quantification of HBsAg and HBV-DNA during therapy with peginterferon alpha-2b plus lamivudine and peginterferon alpha-2b alone in a German chronic hepatitis B cohort.
    Wiegand J, Brosteanu O, Kullig U, Wiese M, Berr F, Maier M, Tillmann HL, Schiefke I.
    Z Gastroenterol; 2011 Nov; 49(11):1463-9. PubMed ID: 22069045
    [Abstract] [Full Text] [Related]

  • 9. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
    Huang Z, Deng H, Zhao Q, Zheng Y, Peng L, Lin C, Zhao Z, Gao Z.
    Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612
    [Abstract] [Full Text] [Related]

  • 10. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels.
    Sonneveld MJ, Hansen BE, Piratvisuth T, Jia JD, Zeuzem S, Gane E, Liaw YF, Xie Q, Heathcote EJ, Chan HL, Janssen HL.
    Hepatology; 2013 Sep; 58(3):872-80. PubMed ID: 23553752
    [Abstract] [Full Text] [Related]

  • 11. Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up study in chronic hepatitis B patients.
    Buster EH, Flink HJ, Simsek H, Heathcote EJ, Sharmila S, Kitis GE, Gerken G, Buti M, de Vries RA, Verhey E, Hansen BE, Janssen HL.
    Am J Gastroenterol; 2009 Oct; 104(10):2449-57. PubMed ID: 19584831
    [Abstract] [Full Text] [Related]

  • 12. Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients.
    Chan HL, Wong GL, Chim AM, Chan HY, Chu SH, Wong VW.
    Antivir Ther; 2011 Oct; 16(8):1249-57. PubMed ID: 22155906
    [Abstract] [Full Text] [Related]

  • 13. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.
    Boglione L, Cusato J, Cariti G, Di Perri G, D'Avolio A.
    Antiviral Res; 2016 Dec; 136():32-36. PubMed ID: 27793564
    [Abstract] [Full Text] [Related]

  • 14. Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.
    Wong VW, Wong GL, Yan KK, Chim AM, Chan HY, Tse CH, Choi PC, Chan AW, Sung JJ, Chan HL.
    Hepatology; 2010 Jun; 51(6):1945-53. PubMed ID: 20209602
    [Abstract] [Full Text] [Related]

  • 15. Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients.
    Ma H, Yang RF, Wei L.
    J Gastroenterol Hepatol; 2010 Sep; 25(9):1498-506. PubMed ID: 20796146
    [Abstract] [Full Text] [Related]

  • 16. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML, Peng CY, Dai CY, Lai HC, Huang CF, Hsieh MY, Huang JF, Chen SC, Lin ZY, Yu ML, Chuang WL.
    PLoS One; 2015 Sep; 10(4):e0122259. PubMed ID: 25835020
    [Abstract] [Full Text] [Related]

  • 17. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype.
    Brunetto MR, Marcellin P, Cherubini B, Yurdaydin C, Farci P, Hadziyannis SJ, Rothe V, Regep L, Bonino F.
    J Hepatol; 2013 Dec; 59(6):1153-9. PubMed ID: 23872601
    [Abstract] [Full Text] [Related]

  • 18. A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B.
    Gish RG, Lau DT, Schmid P, Perrillo R.
    Am J Gastroenterol; 2007 Dec; 102(12):2718-23. PubMed ID: 17662102
    [Abstract] [Full Text] [Related]

  • 19. Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.
    Cao ZH, Ma LN, Zhang HW, Liu YL, Chen XY.
    J Dig Dis; 2013 Aug; 14(8):446-50. PubMed ID: 23615131
    [Abstract] [Full Text] [Related]

  • 20. On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients.
    Goulis I, Karatapanis S, Akriviadis E, Deutsch M, Dalekos GN, Raptopoulou-Gigi M, Mimidis K, Germanidis G, Drakoulis C, Triantos C, Zintzaras E, Bakalos G, Papatheodoridis G.
    Liver Int; 2015 May; 35(5):1540-8. PubMed ID: 25368957
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.